Adriana Gaspar da Rocha

Adriana Gaspar da Rocha

Auto-generated profile, based on publicly available information

Adriana Gaspar da Rocha

Public Health Unit, ULS Baixo Mondego, Figueira da Foz, Portugal Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal Health Investigation and Innovation Institute (i3S), University of Porto, Porto, Portugal

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2013 in Nature Communications
Verified
Journal Article
Open access
PDF file
JVJoão Vinagre
João Vinagre
AAAna Almeida
Ana Almeida
HPHelena Pópulo
Helena Pópulo
RBRui Batista
Rui Batista
JLJoana Lyra
Joana Lyra
Paula SoaresPaula Soares
Paula Soares
Reactivation of telomerase has been implicated in human tumorigenesis, but the underlying mechanisms remain poorly understood. Here we report the presence of recurrent somatic mutations in the TERT promoter in cancers of the central nervous system (43%), bladder (59%), thyroid (follicular cell-derived, 10%) and skin (melanoma, 29%). In thyroid cancers, the presence of TERT promoter mutations (when occurring together with BRAF mutations) is significantly associated with higher TERT mRNA expression, and in glioblastoma we find a trend for increased telomerase expression in cases harbouring TERT promoter mutations. Both in thyroid cancers and glioblastoma, TERT promoter mutations are significantly associated with older age of the patients. Our results show that TERT promoter mutations are relatively frequent in specific types of human cancers, where they lead to enhanced expression of telomerase.

1 May 2014 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
MMMiguel Melo
Miguel Melo
ARAdriana Gaspar da Rocha
Adriana Gaspar da Rocha
JVJoão Vinagre
João Vinagre
RBRui Batista
Rui Batista
JPJoana Peixoto
Joana Peixoto
Paula SoaresPaula Soares
Paula Soares
Context: Telomerase promoter mutations (TERT) were recently described in follicular cell-derived thyroid carcinomas (FCDTC) and seem to be more prevalent in aggressive cancers. Objectives: We aimed to evaluate the frequency of TERT promoter mutations in thyroid lesions and to investigate the prognostic significance of such mutations in a large cohort of patients with differentiated thyroid carcinomas (DTCs). Design: This was a retrospective observational study. Setting and Patients: We studied 647 tumors and tumor-like lesions. A total of 469 patients with FCDTC treated and followed in five university hospitals were included. Mean follow-up (±SD) was 7.8 ± 5.8 years. Main Outcome Measures: Predictive value of TERT promoter mutations for distant metastasization, disease persistence at the end of follow-up, and disease-specific mortality. Results: TERT promoter mutations were found in 7.5% of papillary carcinomas (PTCs), 17.1% of follicular carcinomas, 29.0% of poorly differentiated carcinomas, and 33.3% of anaplastic thyroid carcinomas. Patients with TERT-mutated tumors were older (P < .001) and had larger tumors (P = .002). In DTCs, TERT promoter mutations were significantly associated with distant metastases (P < .001) and higher stage (P < .001). Patients with DTC harboring TERT promoter mutations were submitted to more radioiodine treatments (P = .009) with higher cumulative dose (P = .004) and to more treatment modalities (P = .001). At the end of follow-up, patients with TERT-mutated DTCs were more prone to have persistent disease (P = .001). TERT promoter mutations were significantly associated with disease-specific mortality [in the whole FCDTC (P < .001)] in DTCs (P < .001), PTCs (P = .001), and follicular carcinomas (P < .001). After adjusting for age at diagnosis and gender, the hazard ratio was 10.35 (95% confidence interval 2.01–53.24; P = .005) in DTC and 23.81 (95% confidence interval 1.36–415.76; P = .03) in PTCs. Conclusions: TERT promoter mutations are an indicator of clinically aggressive tumors, being correlated with worse outcome and disease-specific mortality in DTC. TERT promoter mutations have an independent prognostic value in DTC and, notably, in PTC.

6 March 2017 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
MMMiguel Melo
Miguel Melo
ARAdriana Gaspar da Rocha
Adriana Gaspar da Rocha
RBRui Batista
Rui Batista
JVJoão Vinagre
João Vinagre
MMMaria João Martins
Maria João Martins
Paula SoaresPaula Soares
Paula Soares
Context Little is known about the frequency of key mutations in thyroid cancer metastases and its relationship with the primary tumor genotype. Objectives To evaluate the frequency of TERT promoter (TERTp), BRAF, and NRAS mutations in metastatic thyroid carcinomas, analyzing primary thyroid tumors, lymph node metastases (LNMs), and distant metastases. Design and Patients Mutation analysis was performed in 437 tissue samples from 204 patients, mainly with papillary thyroid carcinomas (PTCs; n = 180), including 196 LNMs and 56 distant metastases. All the distant metastases included corresponded to radioiodine-refractory metastatic tissue. Results We found the following mutation frequency in primary PTCs, LNMs, and distant metastases, respectively: TERTp: 12.9%, 10.5%, and 52.4%; BRAF: 44.6%, 41.7%, and 23.8%; and NRAS: 1.2%, 1.3%, and 14.3%. There was a significant concordance between the primary tumor genotype and the corresponding LNM for all the genes, in particular BRAF-mutated PTC. The overall concordance between primary tumors and respective distant metastases was low. In the group of patients with PTCs, we found a high frequency of TERTp mutations and a low frequency of BRAF mutations in distant metastases, in comparison with the paired primary tumors. When present in distant metastases, BRAF mutations frequently coexisted with TERTp mutations. Conclusions When the genotype of primary tumors is compared with the genotype of LNMs, the concordance is high for all the genes studied. On the other hand, distant metastases show an enrichment in TERTp mutations and a decrease in BRAF mutations. TERTp mutations may play a role in distant metastases.

1 January 2018 in Endocrine Connections
Verified
Journal Article
Open access
PDF file
CTCatarina Tavares
Catarina Tavares
MCMaria João Coelho
Maria João Coelho
Catarina EloyCatarina Eloy
Catarina Eloy
MMMiguel Melo
Miguel Melo
ARAdriana Gaspar da Rocha
Adriana Gaspar da Rocha
Paula SoaresPaula Soares
Paula Soares
Thyroid cancer therapy is based on surgery followed by radioiodine treatment. The incorporation of radioiodine by cancer cells is mediated by sodium iodide symporter (NIS) (codified by theSLC5A5gene), that is functional only when targeted to the cell membrane. We aimed to evaluate if NIS expression in thyroid primary tumors would be helpful in predicting tumor behavior, response to therapy and prognosis. NIS expression was addressed by qPCR and immunohistochemistry. In order to validate our data, we also studiedSLC5A5expression on 378 primary papillary thyroid carcinomas from The Cancer Genome Atlas (TCGA) database. In our series,SLC5A5expression was lower in carcinomas with vascular invasion and with extrathyroidal extension and in those harboringBRAFV600E mutation. Analysis ofSLC5A5expression from TCGA database confirmed our results. Furthermore, it showed that larger tumors, with locoregional recurrences and/or distant metastases or harboringRAS,BRAFand/orTERTpromoter (TERTp) mutations presented significantly lessSLC5A5expression. Regarding immunohistochemistry, 12/211 of the cases demonstrated NIS in the membrane of tumor cells, those cases showed variable outcomes concerning therapy success, prognosis and all but one were wild type forBRAF,NRASandTERTp mutations.SLC5A5mRNA lower expression is associated with features of aggressiveness and with key genetic alterations involvingBRAF,RASandTERTp. Mutations in these genes seem to decrease protein expression and its targeting to the cell membrane.SLC5A5mRNA expression is more informative than NIS immunohistochemical expression regarding tumor aggressiveness and prognostic features.

20 February 2015 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MMMiguel Melo
Miguel Melo
ARAdriana Gaspar da Rocha
Adriana Gaspar da Rocha
JVJoão Vinagre
João Vinagre
MSManuel Sobrinho-Simões
Manuel Sobrinho-Simões
Paula SoaresPaula Soares
Paula Soares

7 January 2014 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
Paula SoaresPaula Soares
Paula Soares
RCRicardo Celestino
Ricardo Celestino
ARAdriana Gaspar da Rocha
Adriana Gaspar da Rocha
MSManuel Sobrinho-Simões
Manuel Sobrinho-Simões
The incidence of papillary thyroid microcarcinoma (PTmC) has been increasing everywhere due to the improvement of imaging and morphological diagnoses and probably also due to environmental alterations. Despite this, the mortality caused by thyroid cancer has not increased, reflecting the low clinical aggressiveness of most papillary thyroid carcinomas (PTCs) and the quality of the available treatment. The criteria used to classify PTmC remain questionable, making the clinical risk evaluation of these lesions very difficult. There is no solid basis for establishing the most appropriate tumor size (currently <10 mm) to distinguish PTmC from PTC. Moreover, PTmCs encompass all sorts of PTC histotypes, thus turning the whole group of PTmC genetically and biologically heterogeneous. In this review, we address the 2 most interesting issues from a practical standpoint: Are there any specific morphological or molecular features distinguishing PTmC from PTC? Is it possible to predict the clinical behavior of PTmC in fine needle aspiration biopsy and in surgical specimens, using morphological and/or molecular markers?